Jane Street
LRMR icon

Jane Street’s Larimar Therapeutics LRMR Stock Holding History

Jane Street’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$86K Sell
28,200
-49,000
-63% -$195K ﹤0.01% 10676
2026
Q1 		$347K Buy
+77,200
New +$309K ﹤0.01% 8892
2024
Q2 		– Sell
-10,000
Closed -$75.9K – 9846
2024
Q1 		$75.9K Buy
+10,000
New +$77.9K ﹤0.01% 8635

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Jane Street's LRMR Position: Q2 2026 in Review

Jane Street reduced its Larimar Therapeutics (LRMR) stake by 87% in Q2 2026, selling an estimated $1.91M and leaving 73,736 shares worth $225K. The position accounts for ﹤0.01% of the portfolio, ranked #9854.

Jane Street first reported a position in LRMR in Q1 2016 and has held it in 17 quarters since. The position peaked at $2.59M in Q4 2025. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Jane Street held 73,736 shares of Larimar Therapeutics worth $225K as of Q2 2026.
  • Jane Street sold 480,271 Larimar Therapeutics shares in Q2 2026, an estimated $1.91M.
  • Larimar Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #9854 holding.
  • Jane Street first reported a position in Larimar Therapeutics in Q1 2016 and has held it in 17 quarters since.
  • Jane Street's Larimar Therapeutics position peaked at $2.59M in Q4 2025.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.